EMPATICA SRL

Their core work

Empatica is a Milan-based digital health SME specializing in AI-driven diagnostics and personalized disease management. Their H2020 work spans two distinct clinical areas: automated sleep disorder diagnostics using deep learning, and long-term management of ADHD patients with cardiometabolic comorbidities via mHealth tools and pharmaco-epidemiological methods. They bring machine learning and clinical data science capabilities into large research consortia, translating complex patient data into actionable diagnostic and therapeutic insights. Their commercial positioning is in the intersection of wearable/digital diagnostics and population-level health analytics.

What they specialise in

How they've shifted over time

Both projects launched in 2021, so this is less a temporal evolution and more a parallel expansion into two complementary clinical territories. Their first project (SLEEP REVOLUTION) centres on device-driven, AI-powered physiological diagnostics for sleep disorders — a product-oriented technical niche. Their second project (TIMESPAN) moves toward population health, leveraging national registers, pharmaco-genomics, and epidemiological methods to study chronic disease trajectories in ADHD. The shift signals a broadening from sensor-level diagnostics toward system-level, data-rich clinical research.

Empatica is expanding from device-centric sleep diagnostics into broader population health analytics and pharmaco-epidemiology, suggesting growing ambition in real-world evidence and chronic disease monitoring beyond a single clinical indication.

How they like to work

Empatica joins consortia exclusively as a participant — they have not led any H2020 project. Despite this, they are embedded in notably large networks: 54 unique partners across 24 countries from just 2 projects, which points to membership in major European research consortia rather than niche bilateral collaborations. This profile suggests they contribute a well-defined technical capability (AI diagnostics, digital health tooling) that consortia actively recruit rather than a coordinating or administrative role.

Empatica has collaborated with 54 unique partners across 24 countries — an unusually broad network for an SME with only 2 projects, reflecting participation in large multi-partner RIA consortia. Their reach is pan-European with no discernible geographic concentration beyond their Italian base.

What sets them apart

Empatica is a rare SME that combines commercial digital health product expertise with rigorous clinical research methodology — a pairing that most academic partners lack and most large companies are too slow to deliver. Their dual capability in AI-driven diagnostics (sleep) and pharmaco-epidemiological population studies (ADHD/cardiometabolic) makes them a flexible fit for health consortia needing both a technical tool developer and a data science contributor. For consortium builders, they offer the credibility of an active H2020 participant with a broad European network and a clear track record in two distinct but complementary clinical domains.

Highlights from their portfolio

• TIMESPAN
  Largest funding received (€300,000) and broadest scope, combining ADHD, cardiometabolic disease, pharmaco-genomics, and national register data in a single mHealth-driven intervention running until 2026.
• SLEEP REVOLUTION
  Targets one of Europe's most under-diagnosed conditions (obstructive sleep apnea) using deep learning and digital diagnostics, with clear commercial applications for wearable health device makers.